Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.
International Medullary Thyroid Carcinoma Grading System
Interobserver reproducibility
MTC
Medullary thyroid carcinoma
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
03
05
2022
pubmed:
14
5
2022
medline:
31
8
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Grade, based on proliferative activity and tumor necrosis, has recently been shown to be prognostic in medullary thyroid carcinoma (MTC) in multivariate analysis. The aim of this study was to evaluate the interobserver reproducibility of assessed grade in MTC. Three groups (each group included one resident/fellow and one attending pathologist) independently evaluated a cohort of 44 sporadic MTC. For each case, all available tumor slides were reviewed, and mitotic count and the presence of tumor necrosis were recorded. Ki-67 was performed, and the Ki-67 proliferative index was determined in the area of highest proliferative activity. Tumors were graded according to the recently published International Medullary Thyroid Carcinoma Grading System (IMTCGS). Kappa statistics were calculated for each individual criterion (mitotic count, Ki-67 proliferative index, and necrosis) and for assigned IMTCGS grade. For our cohort of 44 MTCs, the kappa statistic for mitotic count, Ki-67 proliferative index, and necrosis was 0.68, 0.86, and 0.89, respectively. The kappa statistic for assigned IMTCGS grade was 0.87. Our findings indicate that there was a strong level of agreement for assessment of grade in our cohort of MTC, indicating that grade as assessed by the IMTCGS is not only prognostic but also reproducible.
Identifiants
pubmed: 35553368
doi: 10.1007/s12022-022-09718-0
pii: 10.1007/s12022-022-09718-0
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-377Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Williams ED (1966) Histogenesis of medullary carcinoma of the thyroid. Journal of Clinical Pathology 19:114–118
doi: 10.1136/jcp.19.2.114
Tashjian AH, Melvin KEW (1968) Medullary Carcinoma of the Thyroid Gland. New England Journal of Medicine 279:279–283
doi: 10.1056/NEJM196808082790602
Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH (2000) Medullary thyroid carcinoma. Cancer 88:1139–1148
doi: 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z
Opsahl EM, Akslen LA, Schlichting E, et al (2019) Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study. European Thyroid Journal 8:31–40
doi: 10.1159/000493977
Turkdogan S, Forest V-I, Hier MP, Tamilia M, Florea A, Payne RJ (2018) Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer. J of Otolaryngol - Head & Neck Surg 47:55
doi: 10.1186/s40463-018-0303-x
Elisei R, Cosci B, Romei C, et al (2008) Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. The Journal of Clinical Endocrinology & Metabolism 93:682–687
doi: 10.1210/jc.2007-1714
Lindsey SC, Ganly I, Palmer F, Tuttle RM (2015) Response to Initial Therapy Predicts Clinical Outcomes in Medullary Thyroid Cancer. Thyroid 25:242–249
doi: 10.1089/thy.2014.0277
Travis W, Brambilla E, Burke A (2015) WHO classification of tumours of the lung, pleura, thymus and heart., 4th ed. International Agency for Research on Cancer., Lyon
Lloyd R, Osamura R, Kloppel G (2017) WHO classification of tumours of endocrine organs. International Agency for Research on Cancer (IARC), Lyon
Alzumaili B, Xu B, Spanheimer PM, Tuttle RM, Sherman E, Katabi N, Dogan S, Ganly I, Untch BR, Ghossein RA (2020) Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Mod Pathol 33:1690–1701
doi: 10.1038/s41379-020-0532-1
Fuchs TL, Nassour AJ, Glover A, et al (2020) A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. American Journal of Surgical Pathology 44:1419–1428
doi: 10.1097/PAS.0000000000001505
Xu B, Fuchs TL, Ahmadi S, et al (2022) International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. JCO 40:96–104
doi: 10.1200/JCO.21.01329
Najdawi F, Ahmadi S, Capelletti M, Dong F, Chau NG, Barletta JA (2021) Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas. Histopathology 79:427–436
doi: 10.1111/his.14370
Hazard J, Hawk W, Crile G (1959) Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 19:152–61
doi: 10.1210/jcem-19-1-152
Williams ED, Brown CL, Doniach I (1966) Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. Journal of Clinical Pathology 19:103–113
doi: 10.1136/jcp.19.2.103
Ríos A, Rodríguez JM, Acosta JM, Balsalobre MD, Torregrosa N, Sola J, Pérez-Flores D, Parrilla P (2010) Prognostic Value of Histological and Immunohistochemical Characteristics for Predicting the Recurrence of Medullary Thyroid Carcinoma. Ann Surg Oncol 17:2444–2451
doi: 10.1245/s10434-010-1021-4
Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma: Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565
doi: 10.1002/(SICI)1097-0142(19960415)77:8<1556::AID-CNCR20>3.0.CO;2-Y
Franc B, Rosenberg-Bourgin M, Caillou B, et al (1998) Medullary thyroid carcinoma: Search for histological predictors of survival (109 proband cases analysis). Human Pathology 29:1078–1084
doi: 10.1016/S0046-8177(98)90417-8
Tisell LE, Oden A, Muth A, Altiparmak G, Mõlne J, Ahlman H, Nilsson O (2003) The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer 89:2093–2097
doi: 10.1038/sj.bjc.6601453
Mian C, Pennelli G, Barollo S, et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. European Journal of Endocrinology 164:971–976
doi: 10.1530/EJE-11-0079
Baloch ZW, Asa SL, Barletta JA, et al (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33:27–63
doi: 10.1007/s12022-022-09707-3
Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z (2015) Mitotic Count by Phosphohistone H3 Immunohistochemical Staining Predicts Survival and Improves Interobserver Reproducibility in Well-differentiated Neuroendocrine Tumors of the Pancreas. American Journal of Surgical Pathology 39:13–24
doi: 10.1097/PAS.0000000000000341
Ozturk Sari S, Taskin OC, Gundogdu G, Yegen G, Onder S, Keskin M, Saglam S, Ozluk Y, Gulluoglu M, Mete O (2016) The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors. Endocr Pathol 27:162–170
doi: 10.1007/s12022-016-9424-9
Warth A, Fink L, Fisseler-Eckhoff A, et al (2013) Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 462:507–513
doi: 10.1007/s00428-013-1408-2
Swarts DRA, van Suylen R-J, den Bakker MA, et al (2014) Interobserver Variability for the WHO Classification of Pulmonary Carcinoids. American Journal of Surgical Pathology 38:1429–1436
doi: 10.1097/PAS.0000000000000300
McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22:276–282
doi: 10.11613/BM.2012.031
Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M, Papotti MG (2022) Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol 33:155–196
doi: 10.1007/s12022-022-09710-8
Hellgren LS, Stenman A, Paulsson JO, Höög A, Larsson C, Zedenius J, Juhlin CC (2022) Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center. Endocr Pathol. https://doi.org/10.1007/s12022-022-09714-4
doi: 10.1007/s12022-022-09714-4
pubmed: 35305239
pmcid: 9135869
Erickson LA, Mete O, Juhlin CC, Perren A, Gill AJ (2022) Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr Pathol 33:64–89
doi: 10.1007/s12022-022-09709-1
Reid MD, Bagci P, Ohike N, et al (2015) Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol 28:686–694
doi: 10.1038/modpathol.2014.156
Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods. American Journal of Surgical Pathology 36:1761–1770
doi: 10.1097/PAS.0b013e318263207c
Matsukuma K, Olson KA, Gui D, Gandour-Edwards R, Li Y, Beckett L (2017) Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors. Mod Pathol 30:620–629
doi: 10.1038/modpathol.2016.225
Blank A, Wehweck L, Marinoni I, Boos LA, Bergmann F, Schmitt AM, Perren A (2015) Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors. Virchows Arch 467:543–550
doi: 10.1007/s00428-015-1843-3